High dose frusemide in the treatment of hypertension in chronic renal insufficiency and of terminal renal failure

Frusemide in doses up to 2000 mg per day orally has proved a useful adjuvant therapy for resistant hypertension in patients with chronic renal failure, A worth-while diuresis is uncommon if the creatinine clearance is below 2 ml per minute but a useful, though often temporary, effect is obtained in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Postgraduate medical journal 1971-04, Vol.47 (Suppl), p.45
Hauptverfasser: Rastogi, S. P., Volans, G., Elliott, R. W., Eccleston, D. W., Ashcroft, R., Webster, D., Kerr, D. N. S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue Suppl
container_start_page 45
container_title Postgraduate medical journal
container_volume 47
creator Rastogi, S. P.
Volans, G.
Elliott, R. W.
Eccleston, D. W.
Ashcroft, R.
Webster, D.
Kerr, D. N. S.
description Frusemide in doses up to 2000 mg per day orally has proved a useful adjuvant therapy for resistant hypertension in patients with chronic renal failure, A worth-while diuresis is uncommon if the creatinine clearance is below 2 ml per minute but a useful, though often temporary, effect is obtained in the range 2 to 4 ml/min. Above this level of renal function the extent of the diuresis is not reliably predictable from the creatinine clearance but must be found individually for each patient. The dose should be increased with particular caution in patients with chronic pyelonephritis and a creatinine clearance above 10 ml per minute. Side-effects, other than those of excessive diuresis, have been uncommon. Hypokalaemia is readily prevented by the administration of potassium supplements and spironolactone. A rise in plasma urate is common but not usually dramatic and it has not precipitated secondary gout in our experience to date.
doi_str_mv 10.1136/postgradmedj-47-suppl-45
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_journals_1770799243</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3972196001</sourcerecordid><originalsourceid>FETCH-LOGICAL-b316t-aeb22300ce914721440011e0e392b86a42878ad3324f0840667efbc166c7a2943</originalsourceid><addsrcrecordid>eNpNkUtv2zAQhIkiReIm_QkBCOTMli9xpWNiJHHRJD3kcSUoaRXTsR4mKSD-95Vrw-hpgZ1vF4MZQqjgP4RQ5ufQx_QeXN1ivWIaWByHYc109oXMhDYF45CZEzLjXEmWaVBn5FuMK86FAi1OyWmWQQEgZmSz8O9LWvcRaRPGiK2vkfqOpiXSFNClFrtE-4YutwOGhF30fbcDqmXoO1_RgJ1bT4s4No2vPHbVlrqu3p0kDK3fqXumcX49BrwgXxu3jvj9MM_J693ty3zBHv7c_5pfP7BSCZOYw1JKxXmFhdAghdaTe4EcVSHL3Dgtc8hdrZTUDc81NwawKSthTAVOFlqdk6v93yH0mxFjsqt-DJORaAUAh6KQWk3U5YEayylMOwTfurC1h4Amne11HxN-HmUXPqwBBZl9epvb58W9eOOPN_b3xKs9X7arIy243bVm_2_NarD_WrM6U38BJ_WOIQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1770799243</pqid></control><display><type>article</type><title>High dose frusemide in the treatment of hypertension in chronic renal insufficiency and of terminal renal failure</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Rastogi, S. P. ; Volans, G. ; Elliott, R. W. ; Eccleston, D. W. ; Ashcroft, R. ; Webster, D. ; Kerr, D. N. S.</creator><creatorcontrib>Rastogi, S. P. ; Volans, G. ; Elliott, R. W. ; Eccleston, D. W. ; Ashcroft, R. ; Webster, D. ; Kerr, D. N. S.</creatorcontrib><description>Frusemide in doses up to 2000 mg per day orally has proved a useful adjuvant therapy for resistant hypertension in patients with chronic renal failure, A worth-while diuresis is uncommon if the creatinine clearance is below 2 ml per minute but a useful, though often temporary, effect is obtained in the range 2 to 4 ml/min. Above this level of renal function the extent of the diuresis is not reliably predictable from the creatinine clearance but must be found individually for each patient. The dose should be increased with particular caution in patients with chronic pyelonephritis and a creatinine clearance above 10 ml per minute. Side-effects, other than those of excessive diuresis, have been uncommon. Hypokalaemia is readily prevented by the administration of potassium supplements and spironolactone. A rise in plasma urate is common but not usually dramatic and it has not precipitated secondary gout in our experience to date.</description><identifier>ISSN: 0032-5473</identifier><identifier>EISSN: 1469-0756</identifier><identifier>DOI: 10.1136/postgradmedj-47-suppl-45</identifier><identifier>PMID: 5579771</identifier><language>eng</language><publisher>England: The Fellowship of Postgraduate Medicine</publisher><subject>Adolescent ; Adult ; Creatine - blood ; Creatinine - metabolism ; Diuresis ; Female ; Furosemide - administration &amp; dosage ; Furosemide - toxicity ; Gout ; Humans ; Hypertension, Renal - drug therapy ; Hypokalemia - prevention &amp; control ; Kidney Failure, Chronic - drug therapy ; Male ; Metabolic Clearance Rate ; Methyldopa - therapeutic use ; Middle Aged ; Potassium - therapeutic use ; Pyelonephritis - drug therapy ; Sodium - blood ; Sodium - urine ; Spironolactone - therapeutic use ; Urea - blood ; Uric Acid - blood ; Urine - physiology</subject><ispartof>Postgraduate medical journal, 1971-04, Vol.47 (Suppl), p.45</ispartof><rights>Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><rights>Copyright: 2012 Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/5579771$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rastogi, S. P.</creatorcontrib><creatorcontrib>Volans, G.</creatorcontrib><creatorcontrib>Elliott, R. W.</creatorcontrib><creatorcontrib>Eccleston, D. W.</creatorcontrib><creatorcontrib>Ashcroft, R.</creatorcontrib><creatorcontrib>Webster, D.</creatorcontrib><creatorcontrib>Kerr, D. N. S.</creatorcontrib><title>High dose frusemide in the treatment of hypertension in chronic renal insufficiency and of terminal renal failure</title><title>Postgraduate medical journal</title><addtitle>Postgrad Med J</addtitle><description>Frusemide in doses up to 2000 mg per day orally has proved a useful adjuvant therapy for resistant hypertension in patients with chronic renal failure, A worth-while diuresis is uncommon if the creatinine clearance is below 2 ml per minute but a useful, though often temporary, effect is obtained in the range 2 to 4 ml/min. Above this level of renal function the extent of the diuresis is not reliably predictable from the creatinine clearance but must be found individually for each patient. The dose should be increased with particular caution in patients with chronic pyelonephritis and a creatinine clearance above 10 ml per minute. Side-effects, other than those of excessive diuresis, have been uncommon. Hypokalaemia is readily prevented by the administration of potassium supplements and spironolactone. A rise in plasma urate is common but not usually dramatic and it has not precipitated secondary gout in our experience to date.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Creatine - blood</subject><subject>Creatinine - metabolism</subject><subject>Diuresis</subject><subject>Female</subject><subject>Furosemide - administration &amp; dosage</subject><subject>Furosemide - toxicity</subject><subject>Gout</subject><subject>Humans</subject><subject>Hypertension, Renal - drug therapy</subject><subject>Hypokalemia - prevention &amp; control</subject><subject>Kidney Failure, Chronic - drug therapy</subject><subject>Male</subject><subject>Metabolic Clearance Rate</subject><subject>Methyldopa - therapeutic use</subject><subject>Middle Aged</subject><subject>Potassium - therapeutic use</subject><subject>Pyelonephritis - drug therapy</subject><subject>Sodium - blood</subject><subject>Sodium - urine</subject><subject>Spironolactone - therapeutic use</subject><subject>Urea - blood</subject><subject>Uric Acid - blood</subject><subject>Urine - physiology</subject><issn>0032-5473</issn><issn>1469-0756</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1971</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNpNkUtv2zAQhIkiReIm_QkBCOTMli9xpWNiJHHRJD3kcSUoaRXTsR4mKSD-95Vrw-hpgZ1vF4MZQqjgP4RQ5ufQx_QeXN1ivWIaWByHYc109oXMhDYF45CZEzLjXEmWaVBn5FuMK86FAi1OyWmWQQEgZmSz8O9LWvcRaRPGiK2vkfqOpiXSFNClFrtE-4YutwOGhF30fbcDqmXoO1_RgJ1bT4s4No2vPHbVlrqu3p0kDK3fqXumcX49BrwgXxu3jvj9MM_J693ty3zBHv7c_5pfP7BSCZOYw1JKxXmFhdAghdaTe4EcVSHL3Dgtc8hdrZTUDc81NwawKSthTAVOFlqdk6v93yH0mxFjsqt-DJORaAUAh6KQWk3U5YEayylMOwTfurC1h4Amne11HxN-HmUXPqwBBZl9epvb58W9eOOPN_b3xKs9X7arIy243bVm_2_NarD_WrM6U38BJ_WOIQ</recordid><startdate>197104</startdate><enddate>197104</enddate><creator>Rastogi, S. P.</creator><creator>Volans, G.</creator><creator>Elliott, R. W.</creator><creator>Eccleston, D. W.</creator><creator>Ashcroft, R.</creator><creator>Webster, D.</creator><creator>Kerr, D. N. S.</creator><general>The Fellowship of Postgraduate Medicine</general><general>Oxford University Press</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>197104</creationdate><title>High dose frusemide in the treatment of hypertension in chronic renal insufficiency and of terminal renal failure</title><author>Rastogi, S. P. ; Volans, G. ; Elliott, R. W. ; Eccleston, D. W. ; Ashcroft, R. ; Webster, D. ; Kerr, D. N. S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b316t-aeb22300ce914721440011e0e392b86a42878ad3324f0840667efbc166c7a2943</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1971</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Creatine - blood</topic><topic>Creatinine - metabolism</topic><topic>Diuresis</topic><topic>Female</topic><topic>Furosemide - administration &amp; dosage</topic><topic>Furosemide - toxicity</topic><topic>Gout</topic><topic>Humans</topic><topic>Hypertension, Renal - drug therapy</topic><topic>Hypokalemia - prevention &amp; control</topic><topic>Kidney Failure, Chronic - drug therapy</topic><topic>Male</topic><topic>Metabolic Clearance Rate</topic><topic>Methyldopa - therapeutic use</topic><topic>Middle Aged</topic><topic>Potassium - therapeutic use</topic><topic>Pyelonephritis - drug therapy</topic><topic>Sodium - blood</topic><topic>Sodium - urine</topic><topic>Spironolactone - therapeutic use</topic><topic>Urea - blood</topic><topic>Uric Acid - blood</topic><topic>Urine - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rastogi, S. P.</creatorcontrib><creatorcontrib>Volans, G.</creatorcontrib><creatorcontrib>Elliott, R. W.</creatorcontrib><creatorcontrib>Eccleston, D. W.</creatorcontrib><creatorcontrib>Ashcroft, R.</creatorcontrib><creatorcontrib>Webster, D.</creatorcontrib><creatorcontrib>Kerr, D. N. S.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Postgraduate medical journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rastogi, S. P.</au><au>Volans, G.</au><au>Elliott, R. W.</au><au>Eccleston, D. W.</au><au>Ashcroft, R.</au><au>Webster, D.</au><au>Kerr, D. N. S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High dose frusemide in the treatment of hypertension in chronic renal insufficiency and of terminal renal failure</atitle><jtitle>Postgraduate medical journal</jtitle><addtitle>Postgrad Med J</addtitle><date>1971-04</date><risdate>1971</risdate><volume>47</volume><issue>Suppl</issue><spage>45</spage><pages>45-</pages><issn>0032-5473</issn><eissn>1469-0756</eissn><abstract>Frusemide in doses up to 2000 mg per day orally has proved a useful adjuvant therapy for resistant hypertension in patients with chronic renal failure, A worth-while diuresis is uncommon if the creatinine clearance is below 2 ml per minute but a useful, though often temporary, effect is obtained in the range 2 to 4 ml/min. Above this level of renal function the extent of the diuresis is not reliably predictable from the creatinine clearance but must be found individually for each patient. The dose should be increased with particular caution in patients with chronic pyelonephritis and a creatinine clearance above 10 ml per minute. Side-effects, other than those of excessive diuresis, have been uncommon. Hypokalaemia is readily prevented by the administration of potassium supplements and spironolactone. A rise in plasma urate is common but not usually dramatic and it has not precipitated secondary gout in our experience to date.</abstract><cop>England</cop><pub>The Fellowship of Postgraduate Medicine</pub><pmid>5579771</pmid><doi>10.1136/postgradmedj-47-suppl-45</doi></addata></record>
fulltext fulltext
identifier ISSN: 0032-5473
ispartof Postgraduate medical journal, 1971-04, Vol.47 (Suppl), p.45
issn 0032-5473
1469-0756
language eng
recordid cdi_proquest_journals_1770799243
source MEDLINE; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection
subjects Adolescent
Adult
Creatine - blood
Creatinine - metabolism
Diuresis
Female
Furosemide - administration & dosage
Furosemide - toxicity
Gout
Humans
Hypertension, Renal - drug therapy
Hypokalemia - prevention & control
Kidney Failure, Chronic - drug therapy
Male
Metabolic Clearance Rate
Methyldopa - therapeutic use
Middle Aged
Potassium - therapeutic use
Pyelonephritis - drug therapy
Sodium - blood
Sodium - urine
Spironolactone - therapeutic use
Urea - blood
Uric Acid - blood
Urine - physiology
title High dose frusemide in the treatment of hypertension in chronic renal insufficiency and of terminal renal failure
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T08%3A39%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High%20dose%20frusemide%20in%20the%20treatment%20of%20hypertension%20in%20chronic%20renal%20insufficiency%20and%20of%20terminal%20renal%20failure&rft.jtitle=Postgraduate%20medical%20journal&rft.au=Rastogi,%20S.%20P.&rft.date=1971-04&rft.volume=47&rft.issue=Suppl&rft.spage=45&rft.pages=45-&rft.issn=0032-5473&rft.eissn=1469-0756&rft_id=info:doi/10.1136/postgradmedj-47-suppl-45&rft_dat=%3Cproquest_pubme%3E3972196001%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1770799243&rft_id=info:pmid/5579771&rfr_iscdi=true